🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Alkermes plc ALKS R2KR3KPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · Ireland
https://www.alkermes.com
Company Profile ↓
$44.18
+54.31% 1Y
Mkt Cap$7.41B
P/E116.26
P/B3.76
52W High$55.22
52W Low$26.52
Book Value$10.79
EPS (TTM)$0.38

Company Overview

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 15.1% CAGR over the past five years.

Healthy Margins

Operating margin of 15.5% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.48B (-5.2% YoY); net profit $241.66M.
  • Trailing 12 Months Year-on-year growth — revenue +27.0%, earnings -99.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.13%
1 Year:27.00%

Compounded Profit Growth

5 Years:-
1 Year:-99.40%

Stock Price Performance

1 Year:+54.31%
6 Months:+30.29%
3 Months:-16.47%
1 Month:+4.87%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 62% of range
$26.52 $55.22
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)57.31 · Neutral
Price Performance
1M+4.87%
3M-16.47%
6M+30.29%
1Y+54.31%
Valuation vs Sector

P/E of 116.26 is above the sector median of 25.61 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 15.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 116.3.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
116.26
Industry PE
25.61
Forward P/E
24.43
PEG Ratio
1.96
Book Value
$10.79
Price to Book
3.76
P/S
4.09
EV/EBITDA
27.62
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
15.13%
Profit 5Y
-
Revenue (YoY)
27.00%
Earnings (YoY)
-99.40%

Profitability & Returns

ROCE
13.07%
ROE
3.85%
ROA
4.20%
Profit Margin
3.96%
Op Margin
15.50%
Gross Margin
87.18%
EPS (Latest Qtr)
$0.00
EPS (TTM)
$0.38

Balance Sheet & Liquidity

Debt/Equity
0.87
Quick Ratio
1.68
Current Ratio
2.30
Debt
$1.57B
Total Assets
$4.39B
Current Assets
$1.36B
Working Capital
$1.39B

Ownership

Promoter Holding
1.40%
Chg in Prom Hold
-0.00%
FII / Inst Holding
107.45%
Chg in FII Hold
-0.40%

Financial Snapshot

Enterprise Value
$7.41B
Total Revenue (TTM)
$1.67B
EBITDA
$284.93M
Free Cash Flow
$153.38M
Operating Cash Flow
$251.18M
Shares Outstanding
167.76M
Gross Margin
87.18%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALKS Alkermes plc R2KR3KPHARMA 44.18 116.26 $7.41B 0.00% 13.07% 3.85% 15.13% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,306.69 43.95 $1.16T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 267.61 31.05 $644.91B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.19 80.56 $503.96B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 424.98 27.29 $381.46B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 147.24 117.79 $363.27B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 156.27 23.61 $297.02B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 172.57 25.80 $267.64B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 676.54 36.45 $250.15B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ---------191.78M218.84M217.38M225.15M304.64M248.72M223.10M279.87M255.24M246.22M247.53M265.01M251.43M303.72M294.14M278.55M276.22M252.36M287.60M617.40M380.94M350.37M399.13M378.14M-306.51M390.66M394.19M384.55M392.91M496.01M
Cost of Revenue ----------------------------------49.20M49.46M51.59M46.21M61.58M-
Gross Profit ----------------------------------257.31M341.20M342.59M338.34M331.33M-
Operating Expenses ----------------------------------243.52M248.22M253.51M280.23M379.61M-
Operating Income -15.89M-22.82M-32.74M-27.31M-52.52M-77.42M-76.88M-47.12M-61.13M-70.87M-44.51M-38.36M-61.89M-102.00K-37.16M-76.00M-35.92M-53.62M-37.37M-33.66M-10.67M-16.43M4.42M-19.66M-26.59M-34.46M-60.64M-10.97M281.27M89.19M43.31M109.88M104.76M-13.79M92.98M89.08M58.10M-48.28M18.35M
EBITDA ----------------------------------32.91M112.66M108.83M76.50M-21.61M-
Interest Expense ----------------------------------00012.28M20.89M-
Pretax Income ----------------------------------25.49M104.84M100.75M60.38M-61.93M-
Tax Provision ----------------------------------3.02M17.74M17.98M11.04M4.55M-
Net Income -------------62.51M-32.65M-34.44M-96.40M-41.99M-52.88M-38.65M-29.43M-134.00K-22.42M2.36M-28.99M-35.90M-30.14M-63.97M-41.84M237.06M47.76M36.83M91.36M92.38M-22.46M87.10M82.76M49.34M-66.48M501.00K
Diluted EPS -0.170.02-0.27--0.31-----------------0.01-0.18-0.22-0.18-0.39-0.251.380.280.210.530.55-0.130.520.490.29-0.400.00
R&D Expense 52.14M67.21M78.26M70.28M87.88M92.56M101.07M97.01M99.44M104.83M99.15M104.41M108.35M106.82M101.27M102.57M104.44M107.67M93.28M94.22M94.98M92.27M97.47M118.41M95.95M92.87M100.43M63.77M68.22M64.88M67.61M59.65M59.89M-71.82M77.37M81.74M-103.34M112.92M

Profit & Loss (Annual)

Figures in USD.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 178.28M186.64M389.98M575.55M596.33M618.79M628.34M745.69M903.37M1.09B1.17B1.04B-1.11B1.66B1.56B1.48B
Cost of Revenue -------------218.07M253.04M245.33M196.46M
Gross Profit -------------893.73M1.41B1.31B1.28B
Operating Expenses -------------899.82M996.25M891.66M1.03B
Operating Income -43.03M-45.63M-88.28M81.81M34.48M-87.14M-224.30M-208.66M-147.90M-99.13M-175.48M-112.43M--6.09M414.12M420.64M253.96M
EBITDA -------------59.77M519.48M494.86M330.89M
Interest Expense -------------13.04M23.03M22.58M12.28M
Pretax Income --------------31.13M421.52M443.75M291.45M
Tax Provision -------------2.02M-97.64M71.61M49.79M
Net Income -39.63M-45.54M-113.68M24.98M20.65M-30.06M-227.16M-208.44M-157.94M-139.31M-196.62M-110.86M--158.27M355.76M367.07M241.66M
Diluted EPS -0.42-0.48-0.990.180.14-0.21-1.52-----0.70--0.972.102.171.43
R&D Expense 95.36M97.24M141.89M140.01M-272.04M344.40M387.15M412.89M425.41M512.83M394.59M290.92M272.70M270.81M245.33M323.96M

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --452.45M1.44B1.47B1.58B1.92B1.86B1.73B1.80B1.83B1.81B1.95B-1.96B2.14B2.06B2.49B
Current Assets --------------1.13B1.49B1.42B1.93B
Cash & Equivalents 86.89M79.32M38.39M83.60M96.96M167.56M224.06M181.11M186.38M191.30M266.76M203.77M272.96M-292.47M457.47M291.15M388.57M
Inventory --------------181.42M186.41M182.89M196.62M
Receivables --------------216.17M229.58M315.33M268.62M
Total Liabilities --60.43M581.37M517.92M512.40M522.22M541.47M516.94M594.42M653.72M719.96M882.75M-920.23M933.54M590.59M667.70M
Current Liabilities --48.06M89.16M85.93M100.90M130.58M236.21M211.99M291.12M339.77M391.11M438.26M-497.74M520.22M465.20M543.44M
Long Term Debt ---441.36M362.26M357.54M349.01M284.21M280.67M278.44M276.46M274.30M272.12M292.80M290.27M287.73M--
Total Debt --------------379.44M372.19M75.54M70.00M
Total Equity 434.89M412.62M392.02M853.85M952.37M1.07B1.40B1.31B1.21B1.20B1.17B1.09B1.07B-1.04B1.20B1.46B1.82B
Shares Outstanding --------------168.95M172.57M176.67M181.01M

Cash Flows (Annual)

Figures in USD.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -12.25M-5.91M-2.48M---40.36M-63.80M19.19M99.28M72.08M82.84M-21.04M401.35M439.12M520.75M
Investing Cash Flow 28.01M5.63M-417.16M---43.49M127.24M-18.36M-22.20M-141.83M-11.48M--64.54M53.36M-111.31M295.50M
Financing Cash Flow -23.33M-40.65M464.85M--40.89M-58.17M4.08M-1.62M6.76M-2.17M--1.57M-289.71M-494.14M12.38M
Capital Expenditure -15.79M-9.40M-16.99M-22.22M-33.65M-52.88M-43.66M-51.30M-69.43M-90.94M-42.22M--38.26M-48.05M-33.48M-40.42M
Free Cash Flow -28.03M-15.31M-19.47M---93.24M-107.46M-32.11M29.85M-18.86M40.62M--17.21M353.31M405.64M480.33M
Net Change in Cash -------------45.07M165.00M-166.32M828.63M
Share Buybacks 2.68M-------------200.28M-

Ratios (Annual)

Figures in %.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------80.4%84.8%84.2%86.7%
Operating Margin % -24.1%-24.4%-22.6%14.2%5.8%-14.1%-35.7%-28.0%-16.4%-9.1%-15.0%-10.8%--0.5%24.9%27.0%17.2%
Net Margin % -22.2%-24.4%-29.1%4.3%3.5%-4.9%-36.2%-28.0%-17.5%-12.7%-16.8%-10.7%--14.2%21.4%23.6%16.4%
ROE % -9.6%-11.6%-13.3%2.6%1.9%-2.2%-17.3%-17.2%-13.1%-11.9%-18.1%-10.4%--15.2%29.6%25.1%13.3%
ROCE % --11.3%-6.6%5.9%2.3%-4.9%-13.8%-13.8%-9.8%-6.7%-12.4%-7.4%--0.4%25.6%26.4%13.1%

Shareholding Pattern

Insiders
1.40%
Institutions
107.45%
Public Float
108.98%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 17.43% 29.24M $1.19B
2 Baker Bros. Advisors, LP 5.97% 10.01M $406.60M
3 Vanguard Portfolio Management LLC 5.66% 9.49M $385.42M
4 State Street Corporation 5.46% 9.16M $372.01M
5 Vanguard Capital Management LLC 4.48% 7.52M $305.19M
6 Price (T.Rowe) Associates Inc 4.02% 6.74M $273.60M
7 Renaissance Technologies, LLC 3.85% 6.46M $262.38M
8 Geode Capital Management, LLC 2.67% 4.48M $181.85M
9 Dimensional Fund Advisors LP 2.50% 4.19M $170.35M
10 Deep Track Capital, Lp 2.38% 4.00M $162.44M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALKS

Yahoo Finance ue, 20 Oct 2026

Alkermes to Report Third Quarter Financial Results on November 3, 2026

DUBLIN, October 20, 2026--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company’s third quarter financial results.…

Yahoo Finance ue, 20 Oct 2026

Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo Finance ue, 13 Oct 2026

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

DUBLIN, October 13, 2026--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society’s (ESRS) 28t…

Yahoo Finance Fri, 09 Oct 2026

Alkermes (ALKS) Holds To Its Narrative, Is The Pullback A Buying Opportunity?

Alkermes (ALKS) has drawn investor attention after recent trading left the shares about 12% lower over the past month and roughly 23% lower over the past 3 months, despite a solid year-to-date gain. The recent pullback has chipped away at m…

Yahoo Finance Mon, 05 Oct 2026

Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)

Baird Equity Asset Management recently released its “Small/Mid Cap Growth Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund benefited from a sharp rebound in the broader equity market durin…

Yahoo Finance Wed, 30 Sep 2026

LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?

LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.

ALKS — Frequently Asked Questions

What is the current share price of Alkermes plc (ALKS)?

As of 2026-10-22 16:30 PDT, Alkermes plc (ALKS) trades at $44.18 on NasdaqGS. Its 52-week range is $26.52 to $55.22.

What is the market capitalisation of ALKS?

Alkermes plc (ALKS) has a market capitalisation of $7.41B on NasdaqGS.

What is the P/E ratio of ALKS?

ALKS trades at a trailing price-to-earnings (P/E) ratio of 116.26. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 3.76.

What is the return on equity (ROE) of ALKS?

ALKS has a return on equity (ROE) of 3.85%. Its return on capital employed (ROCE) is 13.07%.

Is ALKS a good stock to buy?

This page provides a data-driven analysis of Alkermes plc (ALKS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space